博济医药(300404) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥214,757,945.17, an increase of 69.87% year-over-year, and total revenue for the year-to-date is ¥556,148,773.73, up 55.01% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥13,142,605.26, representing a 143.22% increase year-over-year, with a year-to-date net profit of ¥43,277,754.83, up 87.98%[2] - The basic earnings per share for Q3 2024 was ¥0.0344, a 135.62% increase compared to the same period last year, and year-to-date earnings per share was ¥0.1133, up 81.57%[2] - Operating profit increased by 83.43% to CNY 31,224,117.99 compared to CNY 17,022,123.06 in the same period last year, primarily due to revenue growth[8] - Net profit rose by 82.56% to CNY 45,361,752.11 from CNY 24,847,179.31 year-on-year, driven by increased operating income[8] - Total profit increased by 81.96% to CNY 31,163,247.92 from CNY 17,126,673.03, attributed to higher operating revenue[8] - Basic earnings per share grew by 81.57% to CNY 0.1133 from CNY 0.0624 in the previous year[8] - Total comprehensive income for the period was CNY 44,992,255.06, compared to CNY 25,970,648.33 in the prior year, marking an increase of 73.2%[20] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥1,483,257,656.44, reflecting a 3.80% increase from the end of the previous year[2] - The company reported a significant increase in accounts receivable, which rose by 46.34% to ¥167,435,418.72, attributed to revenue growth[6] - The company’s total liabilities increased, with accounts payable rising by 47.50% to ¥149,639,915.29, reflecting increased project payments[6] - The company reported a significant increase in long-term equity investments, which rose by 61.25% to ¥6,978,057.44, due to additional investments in joint ventures[6] - Current liabilities increased to CNY 417,836,611.43 from CNY 357,510,366.21, reflecting a rise of approximately 17%[18] - The total liabilities amounted to CNY 471,851,682.99, up from CNY 448,819,898.21, indicating a growth of around 5%[18] Cash Flow - The company’s cash flow from operating activities showed a negative net amount of ¥16,040,097.77 year-to-date, indicating a decline of 538.49% compared to the previous year[2] - Net cash flow from operating activities decreased by 538.49% to -CNY 16,040,097.77, primarily due to increased cost expenses[9] - Net cash flow from financing activities fell by 232.98% to -CNY 62,737,410.37, mainly due to increased loan repayments[9] - The company’s cash and cash equivalents decreased to RMB 132.94 million from RMB 397.16 million at the beginning of the period[16] - Cash and cash equivalents at the end of the period decreased to CNY 129,359,171.55 from CNY 160,511,201.49, a decline of 19.4%[22] - The company incurred interest expenses of CNY 2,560,897.37, up from CNY 1,094,453.36, indicating a rise of 134.8%[20] - Investment activities resulted in a net cash outflow of CNY -186,702,227.12, slightly improved from CNY -189,689,242.87 in the previous year[21] - The company paid CNY 46,291,080.46 in debt repayments, significantly higher than CNY 9,257,883.08 in the same quarter last year[22] Expenses and Investments - The company’s financial expenses increased by 271.62% to ¥895,689.19, primarily due to higher interest expenses[7] - The company’s investment income increased by 49.65% to ¥1,481,998.22, driven by higher financial management returns[7] - Research and development expenses were CNY 44,450,607.56, compared to CNY 36,540,647.19 in the previous year, indicating a 22% increase[19] - The company participated as a limited partner in the investment of Daoyuan Angel Equity Investment Fund with a total contribution of RMB 12 million, of which RMB 1 million was contributed by the company[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 22,995, with the largest shareholder holding 31.05%[10] - The largest shareholder, Wang Tingchun, holds 118,674,370 shares, representing 31.05% of the total shares[10] Other Developments - The company increased its new business contract amount to approximately RMB 1.136 billion, representing a year-on-year growth of about 48.13%[14] - The company received government subsidies totaling RMB 2.89 million for its wholly-owned subsidiary, Shenzhen Borui Pharmaceutical Technology Co., Ltd.[14] - The company obtained three invention patents, enhancing its intellectual property portfolio in the pharmaceutical sector[14] - The company’s trading financial assets increased significantly to RMB 148.79 million from RMB 7.38 million at the beginning of the period[16] - Accounts receivable rose to RMB 167.44 million from RMB 114.42 million, indicating improved sales performance[16] - Inventory increased to RMB 228.27 million from RMB 199.07 million, reflecting higher stock levels[16] - Contract assets grew to RMB 94.88 million from RMB 61.15 million, indicating a rise in unbilled revenue[16] - The company’s total restricted shares decreased to 106,636,426 after the release of 5,207,632 restricted shares during the period[13] - Other comprehensive income after tax showed a decrease of 132.89%, resulting in a loss of CNY 369,497.05 compared to a gain of CNY 1,123,469.02 last year[8] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[19]